Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

ABSTRACT:

Background

There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).

Methods

The clinical charts of 233 patients with CRPC treated with enzalutamide were reviewed retrospectively. After 1:3 propensity score matching (PSM), 124 patients were divided into a reduced dose group and a standard dose group, and the prostate specific antigen (PSA) response and the incidence of AEs were compared.

Results

190 patients with CRPC initiated with standard dose enzalutamide were younger and better performance status compared with 43 patients beginning with reduced dose. After PSM, the baseline characteristics were not different between the s

SUBMITTER: Tsuzuki S 

PROVIDER: S-EPMC8486121 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature